CD4 and psoriasis: Here, CD45RO+ primary T cells proved more sensitive to zanolimumab-induced ADCC than naïve CD45RA+T cells.This correlated well with the in vivo findings in psoriasis patients, where subcutaneous infusions (once weekly for 4 weeks) resulted in a dose-dependent decrease in the total lymphocyte counts, mainly due to a reduction in CD4+ T cells in the memory cell subset (CD3+, CD4+, CD45RO+) [21].